ABSTRACT

Curable and incurable sexually transmitted infections (STI) are acquired by hundreds of millions of people worldwide each year. Undiagnosed and untreated STIs cause a range of negative health outcomes including adverse birth outcomes, infertility and other long term sequelae such as cervical cancer. In 2016, the World Health Organization (WHO) launched the Global STI Strategy (2016-2021). The WHO Global STI Strategy’s public health approach focuses on three causative organisms of STIs that need immediate action and for which cost-effective interventions exist: (a) Neisseria gonorrhoeae as a cause of infertility, a risk factor for coinfection with other STIs and because of increasing bacterial resistance to antibiotic treatment, (b) Treponema pallidum given the contribution of syphilis to adverse birth outcomes including stillbirth and neonatal death and (c) Human papillomavirus due to its link to cervical cancer. The range of actions recommended for countries includes: (a) strengthening surveillance, with program monitoring and progress evaluation, (b) STI prevention, (c) early diagnosis of STIs, (d) patient and partner management, and (e) approaches to reach the most vulnerable populations. This summary describes the WHO Global STI Strategy alongside findings from a STI surveillance workshop held in Colombia in May of 2017. Observations related to the Global STI Strategy and findings from the STI estimation workshop are described here for stakeholders in Colombia to consider as they identify opportunities to improve STI services and surveillance.

Key words: Colombia, syphilis, congenital syphilis, chlamydia, gonorrhoea, sexually transmitted infections, infertility, stillbirth, antimicrobial resistance, prevention, strategy, policy, public health.

1. Disclaimer. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.
2. Department of Reproductive Health and Research, World Health Organization, Geneva (Switzerland). Centers for Disease Control and Prevention, Division of STD Prevention, Atlanta (USA). mtaylor@who.int
4. Pan American Health Organization, Bogotá (Colombia).
5. Avenir Health, Geneva (Switzerland).
6. Department of Reproductive Health and Research, World Health Organization, Geneva (Switzerland).
RESUMEN
En el mundo, cientos de millones de personas adquieren anualmente infecciones de transmisión sexual (ITS), algunas de ellas curables y otras incurables. Las ITS que no se diagnostican y no se tratan producen una serie de desenlaces negativos para la salud, entre los cuales se cuentan malos resultados perinatales, infertilidad y otras secuelas crónicas, además del cáncer de cuello uterino. En 2016, la Organización Mundial de la Salud (OMS) lanzó la Estrategia Mundial contra las ITS (2016-2021). El enfoque de salud pública contemplado en la Estrategia Global de la OMS se centra en tres microorganismos causantes de las ITS que requieren acciones inmediatas y para los cuales existen intervenciones costo-efectivas: (a) Neisseria gonorrhoea como causa de infertilidad y factor de riesgo para coinfección con otras ITS, y por su mayor resistencia al tratamiento con antibióticos; (b) Treponema pallidum por la contribución de la sífilis a resultados adversos al nacimiento, entre ellos muerte fetal y muerte neonatal; y (c) virus del papiloma humano debido a su relación con el cáncer de cuello uterino. Entre las acciones recomendadas para los países están las siguientes: (a) fortalecer la vigilancia, el monitoreo y la evaluación de los programas y los avances logrados; (b) prevención de las ITS; (c) diagnóstico temprano de las ITS; (d) manejo del paciente y la pareja; (e) mecanismos para llegar a las poblaciones más vulnerables. Esta síntesis de la política resume la Estrategia Mundial de la OMS contra las ITS, además de los hallazgos de un taller de vigilancia llevado a cabo en Colombia en mayo de 2017. Aquí se describen las observaciones relacionadas con la Estrategia, y los hallazgos del taller a fin de que los distintos grupos de interés en Colombia, los tomen en consideración a la hora de identificar las oportunidades de mejorar los servicios y la vigilancia en lo que atañe a las ITS.

Palabras clave: Colombia, sífilis, sífilis congénita, clamidia, gonorrea, infecciones de transmisión sexual, infertilidad, muerte fetal, resistencia antimicrobiana, prevención, estrategia, política, salud pública.

PURPOSE
This summary provides an overview of priority actions recommended in the WHO Global STI Strategy. These recommendations can be used to build sustainable national and institutional STI capacity and ensure that the most important and cost-effective STI interventions reach the greatest number of people in need. Observations related to the Global STI Strategy and the findings from a national STI burden estimation workshop are described here for stakeholders in Colombia to consider as they identify opportunities to improve STI services and surveillance. A country-level strategy is needed in Colombia to develop and guide effective service delivery strategies within the current health system. Implementing interventions to control STIs will require multi-sectorial collaboration with other relevant health programmes, including maternal and child health, HIV prevention and treatment, adolescent health, and sexual and reproductive health. This broad, collaborative approach can significantly cut costs while amplifying the impact of the STI response.

BACKGROUND: THE STI STRATEGY AND THE IMPORTANCE OF STI CONTROL
Every day around the world, more than one million people acquire a sexually transmitted infection (STI). Some viral STIs, like Human Papillomavirus (HPV) and HIV, are still incurable and can be deadly, but some bacterial STIs – like chlamydia, gonorrhoea, syphilis and trichomoniasis are curable. Sequelae of untreated STIs include: adverse birth outcomes (stillbirth, neonatal death, low birth weight, congenital anomalies), infertility, pelvic inflammatory disease, and ectopic pregnancy. Syphilis outbreaks as well as antimicrobial resistance in gonorrhoea infections are additional emerging STI threats. Besides these burdens, STIs also increase the risk of HIV transmission. Much can be done to control the spread of STIs, alleviate harmful consequences and vastly improve quality of
life. To address this critical health need and enable countries to reach health targets set by the Sustainable Development Goals (SDGs), the World Health Organization (WHO) developed the Global Health Sector Strategy on Sexually Transmitted Infections 2016-2021 (1).

The WHO Global STI Strategy is one of three global health sector strategies developed alongside— the other two strategies address the control of HIV (2) and viral hepatitis (3). These three strategies support an integrated approach using the following common strategic directions: (a) information for focused action; (b) interventions for impact; (c) delivering for equity; (d) financing for stability; and (e) innovation for acceleration. All three strategies contribute to the 2030 Agenda for Sustainable Development and its SDGs (4) as well as the Secretary-General’s Global Strategy for Women’s Children’s and Adolescents’ Health (GSWCAH) (5). The WHO Global STI strategy establishes general guidance for countries to tailor STI prevention activities.

The WHO Global STI Strategy describes priority actions for countries for a stronger and more effective STI response that will help save millions of lives and improve the health of millions more. The range of actions for countries includes: (a) strengthening surveillance, program monitoring and progress evaluation, (b) STI prevention, (c) early diagnosis, (d) patient and partner management, as well as (e) approaches to reach the most vulnerable populations. Use or application of the WHO STI strategy can also support countries to prevent a range of other negative health outcomes resulting from undiagnosed and untreated STIs including adverse birth outcomes, infertility and other long term sequelae, and cervical cancer. The STI Strategy proposes the continuum of quality services – prevention, diagnosis, treatment and cure – to strengthen responses and ensure all populations in need are reached.

The WHO Global STI Strategy’s public health approach focuses on three causative organisms of STIs that need immediate action and for which cost-effective interventions exist: (a) Neisseria gonorrhoeae as a cause of infertility, a risk factor for coinfection with other STIs and because of increasing bacterial resistance to antibiotic treatment; (b) Treponema pallidum given the impact of syphilis on pregnancy outcomes causing more than 350,000 adverse pregnancy outcomes each year (over half of which occur as stillbirths or neonatal deaths) and (c) Human papillomavirus due to its link to cervical cancer with 291 million prevalent cases of HPV, 530,000 new infections and 264,000 deaths each year from cervical cancer. The strategy sets global targets for these three STIs (Box 1).

IMPLEMENTING THE WHO GLOBAL STI STRATEGY

Understanding national STI epidemics is essential to developing a national strategic action plan. The Global STI Strategy urges countries to define a national strategic plan to control STIs that includes key actions (Box 2). These actions help to build a

<table>
<thead>
<tr>
<th>Box 1: WHO Global STI Strategy Targets and Milestones for 2030</th>
</tr>
</thead>
<tbody>
<tr>
<td>• 90% reduction of syphilis incidence globally (2018 global baseline)</td>
</tr>
<tr>
<td>• 90% reduction in gonorrhoeae incidence globally (2018 global baseline)</td>
</tr>
<tr>
<td>• 50 or fewer cases of congenital syphilis per 100,000 live births in 80% of countries</td>
</tr>
<tr>
<td>• Sustain 90% national HPV vaccine coverage, and at least 80% in every district (or equivalent administrative unit), in countries whose national immunization programme includes the HPV vaccine</td>
</tr>
</tbody>
</table>
strong case for STI prevention and care that can rally political commitment and encourage much-needed government and stakeholder investment in STIs. Countries can thereby prioritise and tailor their program strategies and interventions for greatest impact in an STI programme that is feasible, cost-effective, equitable and sustainably financed while strengthening the overall health system (Box 3).

Assessing national progress through STI surveillance, monitoring, and evaluation

Surveillance, monitoring, and evaluation are instrumental in understanding STI trends and guiding program improvements. This includes assessing in which settings and populations STI infections occur, how transmission is facilitated, how effective service access and delivery can succeed in reducing STI spread and/or its health consequences, and what barriers stand in the way of access and use of STI services. A robust surveillance monitoring and evaluation system will help to ensure that programme implementation is on track to achieve service delivery and impact targets as envisioned in the national strategy and plan. STI surveillance programming includes: (a) integration of STI surveillance into the national health information system; (b) increasing the granularity of data by collecting information on risk factors and determinants; (c)

---

**Box 2:**

**Key implementation activities recommended in the WHO Global STI Strategy**

- Identify an institutional home or focal point for STIs within the Ministry of Health
- Create a working group to establish 2018 incidence baseline data and/or estimates for syphilis and gonorrhoea prevalence and incidence, to allow monitoring of progress towards 2030 impact goals
- Strengthen surveillance and conduct a situation analysis to determine in which settings and populations infections are occurring, to inform programming
- Strengthen national programme by
  - reviewing and updating national treatment guidelines,
  - evaluating the national surveillance, monitoring and evaluation system and the quality and programmatic relevance of data that it yields
  - establishing impact targets for the programme
- Develop or update the national STI plan or strategy
- Engage with community, civil society and other partners from the outset to help ensure essential services are available to the entire population
- Establish a solid and sustainable funding base by:
  - Defining the package of essential STI interventions, services, commodities to be included in the national health benefit package
  - Phasing out user fees and strengthening insurance schemes
  - Pooling funds for different diseases
  - Reducing spending on commodities while improving efficiency, through better planning and procurement
identifying specific populations who are at greatest risk of STIs (d) periodic collection of prevalence data for gonorrhea, chlamydia and syphilis through representative sample surveys (both in known key risk populations, as well as in general low-risk populations), (e) capture of routine screening data (e.g. syphilis screening in ANC and in blood donors) and (f) STI case reporting with monitoring of overall trends, key populations with greatest risk of STIs, and program impact. WHO has developed simplified guidance on the core components of STI surveillance and core indicators for monitoring of STI prevalence (figures 1 and 2)(6).

Prevention of STI transmission and acquisition
Combination prevention is the most effective way to prevent the transmission of STIs. Countries can therefore consider prioritizing prevention interventions through effective combination strategies that include: (a) comprehensive health information, education and promotion programmes for adolescents (b) male and female condom programming for protection against both STIs and unintended pregnancies, especially for adolescents (c) use of maternal and child health and family planning clinics to provide additional care and distribute condoms to women at risk of STIs (d) greater use of social marketing to improve supply and demand for STI services and condoms (e) promotion of voluntary male circumcision where appropriate and (f) ensuring access to HPV and hepatitis B vaccination.

Managing symptomatic patients and reaching sex partners
Primary point-of-care outlets – including primary health care clinics, sexual and reproductive health services and services that provide care and management for persons living with HIV – should follow updated management guidelines for symptomatic patients and their sexual partners. This includes: updating implementation plans for symptomatic STI management based on the latest evidence, encouraging the use of single-dose treatment, delivered if possible at a health facility to strengthen patient adherence, and integrating STI testing and treatment into health services for specific populations such as persons with HIV infection. Partner notification plays an essential role in STI
Figure 1. The WHO core components of STI Surveillance (6)

Core components
- Case reporting
- Prevalence assessments
- Etiologies of STI syndromes
- Antimicrobial Resistance monitoring

Objectives
- Magnitude of STI problem in target populations
- Inform treatment recommendations
- Improve programme management
- Improve patient care

Figure 2. Core STI indicators for routine collection (6)

Etiologic
- Gonorrhoeae
- Syphilis
- Congenital syphilis

Syndromic
- Urethral discharge
- Genital ulcer

Screening programs
- Pregnant women
- Sex workers
- MSM

Minimal disaggregation
- Gender: female, male
- Age group: 15-24, >=25
- Syphilis stage: primary/secondary, latent

INTERVENTIONS FOR SUSTAINABILITY AND IMPACT
The impact of these interventions and of an STI programme as a whole can be enhanced by combining STI interventions with other relevant initiatives and programmes such as HIV education, mother and

treatment and care. Activities to strengthen sexual partner management should include: (a) adopting strategies for partner notification and evaluating their implementation (b) safeguarding patient confidentiality and (c) ensuring counselling and treatment of partners.
child health, cancer, immunization or sexual and reproductive health. The packaging of interventions for maximum impact can include ANC screening and treatment of syphilis and HIV, delivery of HPV and hepatitis B vaccines, and controlling the spread of gonococcal antimicrobial resistance (AMR) (Box 4). Strong linkages can significantly improve coverage of interventions and quality of care. The cost of STI interventions can also be reduced when these are delivered in combination with other services.

**Focus on Colombia**

In May of 2017, WHO conducted an STI surveillance workshop in Bogota with the Ministry of Health, to estimate the current and historic STI burden trends using the Spectrum STI estimation model (8-10). Colombia was the first South American country to implement this new surveillance tool, developed by Avenir Health within its broader suite of health planning software tools that is available for free through online download. Participants included ministry of health officials, National Health Institute, representatives of the national laboratory, and selected national STI care providers and academic researchers, as well as country and regional level WHO staff. Input from attendees and findings from the implementation of the Spectrum STI surveillance tool were used to evaluate the quality and utility of STI surveillance, and program progress and impact in Colombia. Priority actions for improving surveillance and program implementation were developed during the workshop, and these are summarized below.

For syphilis, the Spectrum estimations for congenital syphilis showed that recent improvements in ANC-based syphilis screening and treatment coverage since 2009 have resulted in decreasing annual numbers of congenital syphilis cases, but further improvements in both ANC services and in overall control of syphilis in the broader population are needed to accelerate progress towards congenital syphilis elimination (9). Monitoring of syphilis

---

**Box 4:**

**Program combinations to enhance STI intervention**

- **Eliminating mother-to-child transmission (MTCT) of syphilis, HIV and hepatitis B through triple elimination campaigns through:**
  - Screening all pregnant women for HIV and syphilis during ANC, using point-of-care testing ideally with multiplex testing technologies that synergize testing for HIV, syphilis and other infections
  - Providing appropriate injectable penicillin therapy to mothers who are seropositive for syphilis
  - Linking HIV positive pregnant women to clinical HIV care and treatment
  - Integrating hepatitis B vaccination into pre-natal and post-delivery services to eliminate mother-to-child transmission of hepatitis B

- **Ensuring high coverage of HPV and hepatitis B vaccines** by introducing them into national immunization programmes to help reduce cervical cancers and genital warts, and hepatitis B infection through:
  - Integrating the HPV vaccine into cervical cancer prevention activities to increase coverage among adolescents
  - Integrating hepatitis B vaccination into pre-natal and post-delivery services, to eliminate mother-to-child transmission of hepatitis B

- **Controlling the spread of gonococcal antimicrobial resistance (AMR):**
  - Strengthening laboratory capacity for surveillance of AMR
  - Adapting national treatment guidelines to new resistance patterns
  - Training health care providers to provide appropriate treatment
  - Increasing awareness against the systematic use of antibiotics (7)
screening in pregnant women, the proportion diagnosed with syphilis, and the coverage and timeliness of treatment among those found syphilis-infected can inform program improvements and reduce negative birth outcomes due to congenital syphilis. In addition, monitoring pregnant women diagnosed with syphilis and tracking birth outcomes should include assessment of stillbirths and neonatal deaths for evidence of missed maternal syphilis infection. Follow-up and treatment of sexual contacts of pregnant women with syphilis can be strengthened, to reduce chances of re-infection after initial treatment early in the pregnancy and as a strategy to reduce the overall population-level burden of adult syphilis. Continued improvements in syphilis testing and treatment coverage among pregnant women can result in rapid declines in estimates of congenital syphilis. Elimination of congenital syphilis will require not only universal coverage of high-quality ANC-based-screening, but also reducing levels of syphilis in the overall adult population. In Colombia, case reporting and epidemiologic analysis of syphilis cases occurring in non-pregnant adults could inform syphilis prevalence and incidence assessments and could guide identification of “outbreaks” in at-risk populations such as men who have sex with men (MSM), youth, sex workers (SW), prisoners and high risk heterosexual populations. In addition, Laboratory reporting of numbers of syphilis tests performed, persons tested, positive syphilis results and the resulting test positivity rates could improve surveillance of adult syphilis.

For gonorrhoea and chlamydia, a Spectrum-based estimation of completeness of case reporting identified a large number of unreported cases of urethral discharge (a symptom of gonorrhoea and chlamydia). The WHO strategy recommends case reporting of urethral discharge in regions where etiologic diagnosis is not routinely available (figure 2). In addition to syndromic case reporting, WHO recommends systematic case reporting for gonorrhoea and chlamydia cases, and case reporting trends should be analysed alongside statistics of numbers of etiological tests conducted and the resulting test positivity rates. Periodic etiologic evaluation of a sample subset of patients with STI syndromes are also recommended (figure 1), to support interpretation of syndromic case reports, inform syndromic treatment guidelines, and monitor evolution of antimicrobial resistance. In Colombia, this will require expanded laboratory capacity to perform routine diagnostic testing for gonorrhoea and chlamydia.

WHO recommends as part of the Global STI strategy the performance of prevalence assessments of gonorrhoea and chlamydia in general populations (such as pregnant women) (figure 1) These surveys, when conducted periodically (e.g. every 2 years) are ideal to assess national STI burden. Colombia has not had any nationally representative gonorrhoea and chlamydia prevalence surveys and national surveys may remain beyond the scope of surveillance capacity. As a feasible option Colombia may consider periodic screening for gonorrhoea and chlamydia within existing health activities, such as in samples of pregnant women in ANC, or in blood donors.

Early and correct diagnosis of STIs is the best way to ensure effective medical treatment and prevent further STI transmission. An evaluation of patient access to, and quality of, diagnosis and treatment for symptoms of STIs in Colombia is needed. The current medical setting may present barriers to the use of structured STI care, with patients resorting to self- treatment through pharmacies without medical evaluation. Expanded laboratory capacity to diagnose gonorrhoea, chlamydia and other STIs that is accessible by general medical providers can reduce inadequate or inappropriate treatment of STI symptoms. Scale-up and use of WHO prequalified rapid point-of-care diagnostics for syphilis screening in pregnant women and high risk populations can expand screening and treatment coverage and reduce treatment delays. Reducing delays and loss-to-follow-up between collecting specimens, laboratory testing, and access to treatment can reduce the risk of transmission and disease sequelae.
These activities can be considered alongside efforts to ensure wide acceptance of prevention interventions, elimination of stigma and discrimination in health care settings, and early availability of prevention and treatment services. Provider interventions including clinical training in STI diagnosis and management as well as interactive supervision of compliance with diagnosis and treatment guidelines should be included to expand clinical personnel capacity to address STIs. Taken together, the above actions and those recommended in the WHO Global STI Strategy will intensify the national STI response in Colombia and ensure progress towards ending sexually transmitted infections while improving health and well-being.

REFERENCES

Conflicto de intereses: ninguno declarado.